Novel Experimental COVID Therapies Affecting Host Response

About this Study

The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing progression to critical illness, multiorgan failure, or death. Our objective is to determine whether modulating the host tissue response with agents targeting the RAAS improves clinical outcomes among patients with COVID-19.

Sponsor Protocol ID:pending
IRB Number:pending
Pending Activation
Phase 2
October 15, 2021
Eligibility Criteria
18 years old
Both Male and Female

Inclusion Criteria1.  Hospitalized for COVID-19

2.  ≥18 years of age

3.  Symptoms or signs of acute COVID-19, defined as one or more of the following:
a) cough
b) reported or documented body temperature of 100.4o F or greater
c) shortness of breath
d) chest pain
e) infiltrates on chest imaging (x-ray, CT scan, lung ultrasound)

Exclusion Criteria1.  COVID-19 symptom onset >14 days prior to randomization

2.  Hospitalized for >72 hours prior to randomization

3.  Pregnancy

4.  Breastfeeding

5.  Prisoners

6.  End-stage renal disease

7.  Patient and/or clinical team is not pursuing full medical management 

8.  Known severe renal artery stenosis

9.  Known significant left ventricular outflow obstruction

10.  Randomized in another trial evaluating RAAS modulation in the prior 30 days

11.  The treating clinician expects inability to participate in study procedures or participation would not be in the best interests of the patient

Categories Click category to view its trials.
COVID-19 (Coronavirus)
Emergency Medicine
Participating Locations
University Hospital - UMMC
Contact Information
Contact Name: Rebekah Peacock
Principal Investigator:Jones, Alan E, M.D.
How to participate in our Clinical Trials